Wuhan YZY Biopharma Co (HKSE:02496) Cash-to-Debt : 2.18 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Wuhan YZY Biopharma Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Wuhan YZY Biopharma Co's cash to debt ratio for the quarter that ended in Dec. 2023 was 2.18.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Wuhan YZY Biopharma Co could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Wuhan YZY Biopharma Co's Cash-to-Debt or its related term are showing as below:

HKSE:02496' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.18 Med: 2.62 Max: 3.6
Current: 2.18

During the past 3 years, Wuhan YZY Biopharma Co's highest Cash to Debt Ratio was 3.60. The lowest was 2.18. And the median was 2.62.

HKSE:02496's Cash-to-Debt is ranked worse than
65.49% of 1527 companies
in the Biotechnology industry
Industry Median: 6.24 vs HKSE:02496: 2.18

Wuhan YZY Biopharma Co Cash-to-Debt Historical Data

The historical data trend for Wuhan YZY Biopharma Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Wuhan YZY Biopharma Co Cash-to-Debt Chart

Wuhan YZY Biopharma Co Annual Data

Trend

Dec21

Dec22

Dec23

Cash-to-Debt

3.60

2.62

2.18

Wuhan YZY Biopharma Co Semi-Annual Data
	Dec21	Dec22	Dec23
Cash-to-Debt	3.60	2.62	2.18

Competitive Comparison of Wuhan YZY Biopharma Co's Cash-to-Debt

For the Biotechnology subindustry, Wuhan YZY Biopharma Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wuhan YZY Biopharma Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Wuhan YZY Biopharma Co's Cash-to-Debt falls into.

Wuhan YZY Biopharma Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Wuhan YZY Biopharma Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	215.129	/	(98.401	+	0.164)
	=	2.18

Wuhan YZY Biopharma Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	215.129	/	(98.401	+	0.164)
	=	2.18

Wuhan YZY Biopharma Co (HKSE:02496) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Wuhan YZY Biopharma Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Wuhan YZY Biopharma Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan YZY Biopharma Co (HKSE:02496) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan YZY Biopharma Co Ltd (HKSE:02496) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 666 Gaoxin Road, East Lake High Tech, Development Zone, Hubei Province, Wuhan, CHN

Website

https://en.yzybio.com/

Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing new class of innovative medicines in respect to anti-tumor bispecific antibody.

Executives

Dragon Merit Holdings Limited	2201 Interest of corporation controlled by you
Robust Sun Holdings Limited	2201 Interest of corporation controlled by you
Cspc Pharmaceutical Group Limited	2201 Interest of corporation controlled by you
Shi Yao Ji Tuan En Bi Pu Yao Ye You Xian Gong Si	2101 Beneficial owner
He Bei Yi Er Qi Ye Guan Li Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Mei Shan Bao Shui Gang Qu Guang Rui Hong Xiang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Guo Xin Si Chuang Tou Zi Ji Jin Guan Li Bei Jing You Xian Gong Si	2201 Interest of corporation controlled by you
Guo Hong Wei
Nan Jing Cai Zhi Er Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Nan Ning Hui You Xing Yao Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Nan Ning Yao You Shang Wu Zi Xun He Huo Qi Ye You Xian He Huo
Wen Zhi Cheng
Tong De Qian Yuan Bei Jing Tou Zi Guan Li You Xian Gong Si
Wang Hongjie	2201 Interest of corporation controlled by you
Wu Shangzhi	2201 Interest of corporation controlled by you

Wuhan YZY Biopharma Co (HKSE:02496) Headlines

No Headlines